Evidence map›Paper›PMID 24142306›Full record

ReviewBrain imaging and behavior2014

Neuroimaging and genetic risk for Alzheimer's disease and addiction-related degenerative brain disorders.

Florence F Roussotte, Madelaine Daianu, Neda Jahanshad, Cassandra D Leonardo, Paul M Thompson

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Brain imaging and behavior, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.9field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Florence F Roussotte *Imaging Genetics Center, Laboratory of Neuro Imaging, Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Madelaine Daianu *Imaging Genetics Center, Laboratory of Neuro Imaging, Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Neda JahanshadImaging Genetics Center, Laboratory of Neuro Imaging, Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Cassandra D LeonardoImaging Genetics Center, Laboratory of Neuro Imaging, Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Paul M ThompsonImaging Genetics Center, Laboratory of Neuro Imaging, Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
University of California, Los Angeles · US

Funding

TR&D3: Intrinsic Surface MappingP41EB015922 · NIBIB · UNIVERSITY OF SOUTHERN CALIFORNIA · PI VAN HORN, JOHN DARRELL · 2012 to 2022
$14.1M
Systems in Integrative BiologyT32GM008185 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CHOU, TOM · 1987 to 2022
$4.6M
Alzheimer's disease risk analyzed using population imaging genomicsR01AG040060 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI THOMPSON, PAUL M · 2011 to 2016
$2.5M
Empowering Personalized Medicine: Integrating Imaging, Genetics, and BiomarkersR01MH097268 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI COPPOLA, GIOVANNI, THOMPSON, PAUL M · 2012 to 2014
$1.3M
NIA NIH HHS R01 AG040060NIBIB NIH HHS P41 EB015922NIGMS NIH HHS T32 GM008185NIMH NIH HHS R01 MH097268NIMH NIH HHS R01MH097268
6 · The paper itself

Abstract

Neuroimaging offers a powerful means to assess the trajectory of brain degeneration in a variety of disorders, including Alzheimer's disease (AD). Here we describe how multi-modal imaging can be used to study the changing brain during the different stages of AD. We integrate findings from a range of studies using magnetic resonance imaging (MRI), positron emission tomography (PET), functional MRI (fMRI) and diffusion weighted imaging (DWI). Neuroimaging reveals how risk genes for degenerative disorders affect the brain, including several recently discovered genetic variants that may disrupt brain connectivity. We review some recent neuroimaging studies of genetic polymorphisms associated with increased risk for late-onset Alzheimer's disease (LOAD). Some genetic variants that increase risk for drug addiction may overlap with those associated with degenerative brain disorders. These common associations offer new insight into mechanisms underlying neurodegeneration and addictive behaviors, and may offer new leads for treating them before severe and irreversible neurological symptoms appear.

Indexed as

Alzheimer DiseaseBrainGenetic Predisposition to DiseaseHumansNeurodegenerative DiseasesNeuroimagingSubstance-Related Disorders

Identifiers

PMID24142306
PMCPMC3992278
OpenAlexW1975735271

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.